Details for Patent: 9,604,948

Which drugs does patent 9,604,948 protect, and when does it expire?

Patent 9,604,948 protects VERQUVO and is included in one NDA.

This patent has one hundred and twenty-three patent family members in forty-four countries.

Summary for Patent: 9,604,948

Title:	Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Abstract:	The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) ##STR00001## which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) ##STR00002## which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
Inventor(s):	Fey; Peter (Wuppertal, DE), Grunenberg; Alfons (Wuppertal, DE), Bierer; Donald (Haan, DE)
Assignee:	ADVERIO PHARMA GMBH (Schoenefeld, DE)
Application Number:	14/796,703
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process;

Drugs Protected by US Patent 9,604,948

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No			Y	Y		REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No			Y	Y		REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes			Y	Y		REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Foreign Priority and PCT Information for Patent: 9,604,948

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	11190789	Nov 25, 2011
	11192301	Dec 7, 2011

International Family Members for US Patent 9,604,948

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3898
Argentina	088983
Argentina	125027
Australia	2012342547
Australia	2017254916
Australia	2019202123
Brazil	112014012414